We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (452)7/19/1999 8:50:00 PM
From: John Metcalf  Respond to of 579
{Pfizer ethics} Pfizer is becoming its own Viagra joke, having rocketed off for awhile and staying up longer than expected....

Pfizer is pleading guilty in a price-fixing scheme. They continued the illegal practice 15 years, and were only fined $20mm, or $1.3mm per year, to view it coldly. Our regulatory apparatus can be quite reasonable to rent!

From curiosity, I read the litigation sections from PFE's 10-Q and 10-K. More good news! Pfizer's attorneys are way too busy to spend much time with Sibia. If they follow a frequent PFE strategy of extending litigation for years, Sibia won't be hurt by it, being able to practice and license their invention in the meantime.

To: scaram(o)uche who wrote (452)7/21/1999 9:56:00 AM
From: scaram(o)uche  Respond to of 579
1508Y results negative. Studies insufficiently powered. Lilly gets a year to look at.......... "a trend to significance was noted and significant differences
between doses of altinicline were observed, suggesting a dose-response effect."

To: scaram(o)uche who wrote (452)7/21/1999 9:57:00 AM
From: A.J. Mullen  Read Replies (1) | Respond to of 579
Ignore this! Richard beat me to it. eom.